Clinical trials: MASLD
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Effects of Long-lasting Bicarbonate-Sulfate-Calcium-Magnesium Water Intake on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Outcome
Background: Fonte Essenziale®, a mineral water rich in bicarbonate, sulphate, calcium, and magnesium, has shown potential in modulating the gut-liver axis and microbiota in hepatic steatosis.
- Trial name
- FonteESSEMASLD (NCT07211113)
- Testing
- Fonte Essenziale® mineral water
- Where
- Italy
- Volunteers
- 87 people
- Sponsor
- University of Campania Luigi Vanvitelli
Hyperoxaluria, Nonalcoholic Fatty Liver Disease
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
The purpose of this study is to test the safety of BMN 255 and to learn about the effect BMN 255 has on you and your hyperoxaluria associated with NAFLD, and compare these effects with a placebo.
- Conditions
- Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
- Trial name
- NCT06138327
- Testing
- BMN 255
- Where
- 7 sites in United States
- Sponsor
- BioMarin Pharmaceutical
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly
Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly
This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly, Nonalcoholic Fatty Liver (NAFL), Nonalcoholic Fatty Liver Disease (NAFLD)
- Trial name
- HEPACT (NCT07068191)
- Testing
- Dietary supplement "Gepaktiv", UDCA (Ursodeoxycholic acid), Ademetionine
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Phenomen Pharma
Coronary Artery Disease, Arterial Stiffness, Blood Pressure
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018.
- Conditions
- Coronary Artery Disease, Arterial Stiffness, Blood Pressure, AORTIC VALVE DISEASES, Mitral Valve Stenosis and/or Insufficiency
- Trial name
- SCAPIS-ReEx (NCT07476703)
- Testing
- Coronary computer tomography (CCTA), Echocardiograhy and aortic ultrasound, Liver elastography
- Where
- Sweden
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease
OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
The goal of this clinical trial is to learn if the use of a care model including teleconsults and the EMPOWER app can induce clinically significant weight loss and metabolic improvements in obese adults with diabetes and…
- Conditions
- Obesity and Type 2 Diabetes, NAFLD - Non-Alcoholic Fatty Liver Disease, Hypertension, Dyslipidaemia
- Trial name
- OneSTOP (NCT06890169)
- Testing
- OneSTOP program, Standard of care weight management program
- Where
- Singapore
- Volunteers
- 120 people
- Sponsor
- Changi General Hospital
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Early Motherhood
Temporal Eating Patterns and Metabolic Health
Obesity and its related health problem, like fatty liver disease and type 2 diabetes, are major health problems worldwide and can lead to serious illness and reduced quality of life.
- Trial name
- TIME-MET (NCT07630636)
- Where
- United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Maria Chondronikola
Metabolic Associated-dysfunction Steatotic Liver Disease (MASLD)
Time-restricted Feeding in MASLD
The recommended treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) currently focuses on lifestyle changes, including dietary adjustments and increased physical activity.
- Trial name
- MASLD-Interval (NCT07530809)
- Testing
- time-restricted feeding in a 5:2 regimen
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universität des Saarlandes
Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism
Hypothyroidism and Liver Fibrosis Severity in MASLD
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide, characterized by excess fat accumulation in the liver associated with metabolic risk factors such as obesity and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Hypothyroidism, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07793279
- Volunteers
- 85 people
- Sponsor
- Assiut University
MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.
The goal of this clinical trial is to study the effect of a time-restricted eating (TRE) dietary pattern combined with a time of consumption restriction about the daily portions of fruits and vegetables in people diagnosed with…
- Conditions
- MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD, NAFLD - Non-Alcoholic Fatty Liver Disease
- Trial name
- CHRONOMASLD (NCT06705868)
- Testing
- Diet-Time-restricted eating (TRE), Lifestyle Management
- Where
- Cyprus
- Volunteers
- 150 people
- Sponsor
- Cyprus University of Technology
HCC, MASLD
Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer
Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the leading cause of chronic liver disease, accounting for an increasing burden of cirrhosis, hepatocellular carcinoma (HCC), and related mortality…
- Trial name
- NCT07775716
- Testing
- Comprehensive Genomic and Transcriptomic Profiling, Patient-Derived Human Liver Organoid (HLO) Development, AI-Driven Digital Pathology (HistoIndex)
- Where
- Italy
- Volunteers
- 35,500 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico